Lincoln Pharmaceuticals Limited (BSE: 531633, NSE: LINCOLN) has reported a consolidated net profit of Rs. 20.01 crore for the Q2 FY 2025-26 as compared to the net profit of Rs. 26.35 crore reported in Q2 FY 2024-25. Total income for the quarter ended September 2025 was reported at Rs. 170.60 crore as compared to the total income of Rs. 171.19 crore in Q2 FY2024-25. EBITDA for Q2 FY26 was reported at Rs. 32.66 crore as compared to EBITDA of Rs. 38.35 crore in Q2 FY25. Shareholders at the 31st Annual General Meeting (AGM) approved a dividend of Rs. 1.80 per share (18%) for the FY 2024-25.
The company is targeting a revenue of Rs. 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Company is committed to expanding its global footprint while meeting diverse healthcare needs. Foreign Institutional Investors (FIIs) have steadily raised their holding in the company to 4.73% as on 30th September 2025.
2025 (H1FY26), The company has reported standalone net profit of Rs. 47.71 crore as compared to the net profit of Rs. 50.03 crore in H1 FY25. Total Income for the H1 FY26 was reported at Rs. 339.93 crore as compared to H1 FY25 total income of Rs. 328.88 crore. EBITDA for the H1 FY26 ended September 2025 was reported at Rs. 71.74 crore as compared to Rs. 71.50 crore EBITDA in H1 FY25. EPS for H1 FY26 was reported at Rs. 23.79 per share.
The company’s growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards
